Page 1

Cardiff Oncology ™ Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF - 004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI / bevacizumab into planned registrational program for first - line RAS - mutated mCRC Following successful End - of - Phase 2 meeting with FDA , Company aligned on key elements of registrational trial ; plans to initiate study in Q1 2027 , subject to securing additional financing Completed $ 10 million Registered Direct offering , extending cash runway SAN DIEGO , Calif . , August 11 , 2026 - Cardiff Oncology , Inc. ( Nasdaq CRDF ) , a clinical - stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies , today announced financial results for the second quarter ended June 30 , 202 , and provided a business update . “ The second quarter was an important period of progress for Cardiff , highlighted by the presentation of positive Phase 2 data at ASCO and our continued progress in preparation for a planned registrational trial of onvansertib in first - line RAS - mutated metastatic colorectal cancer , " said Mani Moħindru , PhD , President and Chief Executive Officer of Cardiff Oncology . “ The updated CRDF - 004 results reinforced our confidence in the selected registrational dose and regimen of 30 mg onvansertib in combination with FOLFIRI / bevacizumab . This regimen has demonstrated deep and durable tumor shrinkage over time , reflecting the synergistic mechanisms of action , while maintaining a well - tolerated safety profile with no overlapping or new to icities when added to standard- of - care therapy . " Dr. Mohindru continued , “ Following our successful End - of - Phase 2 meeting with the FDA , we are preparing to initiate the planned Phase 3 trial in the first quarter of 2027 , subject to securing additional financing . We believe the totality of data generated to date strengthens onvansertib's potential to become an important new treatment option for patients with first - line RAS - mutated metastatic colorectal cancer , an area where there remains significant unmet need . " Clinical and Regulatory Highlights Presented Positive Results from Randomized , Controlled Phase 2 CRDF - 004 Trial at the 2026 American Society of Clinical Oncology " ASCO " ) Annual Meeting In June , Cardiff presented positive results from CRDF - 004 , its ongoing , randomized , controlled , dose - finding Phase 2 clinical trial evaluating onvansertib in combination with standard - of - care ( " SoC " ) regimens in patients with first- line RAS - mutated metastatic colorectal cancer ( " mCRC ” ) , in a rapid oral presentation at the 202 ASCO Annual Meeting . The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib plus SoC regimen for the registrational program . The selected regimen , 30 mg onvansertib in combination with FOLFIRI / bevacizumab ( " bev " ) , demonstrated deep and durable tumor shrinkage , including clinically